The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASCO GI 2021 | Updates in the use of neratinib in fibrolamellar carcinoma and biliary tract cancer

Name: Updates in the use of neratinib in fibrolamellar carcinoma and biliary tract cancer
Uploaded: 2021-01-21T00:00:00Z
Duration: 2 min 21 s
Description: Ghassan Abou-Alfa, MD, Memorial Sloan-Kettering Cancer Center, New York City, NY, updates us on the use of neratinib in both fibrolamellar carcinoma and biliary tract cancer, the latter of which where neratinib was evaluated in combination with immune checkpoint blockade.This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Ghassan Abou-Alfa • 21 Jan 2021

ASCO GI 2021

Bile Duct Cancer Gastrointestinal Cancer Everolimus Neratinib Nivolumab Pembrolizumab

SUMMIT

Ghassan Abou-Alfa, MD, Memorial Sloan-Kettering Cancer Center, New York City, NY, updates us on the use of neratinib in both fibrolamellar carcinoma and biliary tract cancer, the latter of which where neratinib was evaluated in combination with immune checkpoint blockade.This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).